23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › CRISPR THERAPEUTICS AG › 2023-2024

CRISPR THERAPEUTICS AG 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and CRISPR THERAPEUTICS AG’s Form 8-K, filed June 3, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 37Reported items
  • 439Asset managers, any item
  • 4,919Fund votes
  • May 30, 2024Meeting date

Results at a glance

Meeting of May 30, 2024: 24 items on CRISPR THERAPEUTICS AG’s Form 8-K, filed June 3, 2024: 14 elected · 8 approved · 1 passed (calculated) · 1 not approved.

Not approved or not elected

  • 14. Transaction of Any Other Business 48.1% of votes cast Not approved Under 80%

Dissent

Significant dissent: 4 directors (34.3%, 32.9%, 23.1%, 21.3% against).

  • Elect Director: Ali Behbahani, M.D. 66% of votes cast Elected Significant · 34.3% against
  • Elect Director: Ali Behbahani, M.D. 67% of votes cast Elected Significant · 32.9% against
  • Elect Director: Simeon J. George, M.D. 77% of votes cast Elected Significant · 23.1% against
  • Elect Director: Simeon J. George, M.D. 79% of votes cast Elected Significant · 21.3% against

Notable dissent: 4 directors (19.9%, 18.8%, 18.7%, 17.6% against); 1 say-on-pay vote (74.9% support); 2 equity or compensation plans (24.2%, 19.9% against); 1 other board item (21.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CRISPR THERAPEUTICS AG in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by CRISPR THERAPEUTICS AG

These tallies are CRISPR THERAPEUTICS AG’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CRISPR THERAPEUTICS AG — official shareholder meeting results, meeting held May 30, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
1. Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2023 60,823,544226,925244,210 --0 99.6%Approved—
2. Approval of the Appropriation of Financial Results 60,715,908283,326295,445 --0 99.5%Approved—
3. Discharge of the Members of the Company's Board of Directors and Executive Committee 42,727,165171,815123,325 --18,272,374 99.6%Approved—
Elect Director: Samarth Kulkarni, Ph.D. 42,442,977503,26576,063 --18,272,374 99%Elected—
Elect Director: Ali Behbahani, M.D. 28,820,24714,118,17283,886 --18,272,374 67%Elected—
Elect Director: Maria Fardis, Ph.D. 42,253,383689,28179,641 --18,272,374 98%Elected—
Elect Director: H Edward Fleming Jr., M.D. 35,393,6297,547,60981,067 --18,272,374 82%Elected—
Elect Director: Simeon J. George, M.D. 33,809,7699,131,33881,198 --18,272,374 79%Elected—
Elect Director: John T. Greene 34,903,0548,038,35980,892 --18,272,374 81%Elected—
Elect Director: Katherine A. High, M.D. 42,672,595274,92874,782 --18,272,374 99.4%Elected—
Elect Director: Douglas A. Treco, Ph.D. 40,807,8712,133,55180,883 --18,272,374 95%Elected—
Elect Director: Sandesh Mahatme, LL.M. 42,762,070177,63382,602 --18,272,374 99.6%Elected—
Elect Director: Christian Rommel, Ph.D. 42,777,061162,39882,846 --18,272,374 99.6%Elected—
Elect Director: Ali Behbahani, M.D. 28,182,97014,734,499104,836 --18,272,374 66%Elected—
Elect Director: H Edward Fleming Jr., M.D. 34,866,3148,048,771107,220 --18,272,374 81%Elected—
Elect Director: Simeon J. George, M.D. 32,981,2709,932,010109,025 --18,272,374 77%Elected—
Elect Director: John T. Greene 34,374,4398,540,932106,934 --18,272,374 80%Elected—
7. Non-Binding Advisory Vote on the Compensation Paid to Named Executive Officers Under U.S. Securities Law Requirements 32,094,73710,778,822148,746 --18,272,374 75%Approved—
8. Approval of an Increase in the Conditional Share Capital for Employee Equity Plans 32,512,49410,394,452115,359 --18,272,374 76%Approved—
9. Approval of Amendment to the 2018 Stock Option and Incentive Plan 34,337,9538,532,315152,037 --18,272,374 80%Approved—
10. Approval of Amendments to the Articles of Association to Facilitate the Use of Equity Compensation and Pension Benefits Programs Consistent with Current Market Practices 33,909,6898,995,908116,708 --18,272,374 79%Approved—
11. Approval of an Increase and Certain Adjustments to the Company’s Capital Band 58,625,9382,209,165459,576 --0 96%Approved—
13. Re-election of the Auditors 60,337,355352,399604,925 --0 99.4%Passed (calculated)—
14. Transaction of Any Other Business 20,311,83521,901,628808,842 --18,272,374 48.1%Not approved—

This meeting is also recorded here as May 31, 2024; both records come from the same filing, so the date should be checked against it.

Source: CRISPR THERAPEUTICS AG, Form 8-K, filed with the SEC on June 3, 2024 — read the filing on EDGAR.

How asset managers voted at the CRISPR THERAPEUTICS AG 2023-2024 meeting

439 asset managers disclosed a vote on at least one CRISPR THERAPEUTICS AG item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CRISPR THERAPEUTICS AG’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Discharge of the Members of the Company's Board of Directors and Executive Committee

Official resultCORPORATE GOVERNANCEReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 42,727,165AGAINST: 171,815
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Discharge of the members of the Board of Directors and the Executive Committee.

CRISPR THERAPEUTICS AG’s own tally for this item (“3. Discharge of the Members of the Company's Board of Directors and Executive Committee”): 42,727,165 for, 171,815 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Discharge of the Members of the Company's Board of Directors and Executive Committee The discharge of the members of the Company’s Board of Directors and the Executive Committee from personal liability for their activities during the year ended December 31, 2023 was approved.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 17,945,546 for, 1,000 unknown.

FOR
FOR: 17,945,546UNKNOWN: 1,000
Largest asset managers voting on “Discharge of the members of the Board of Directors and the Executive Committee.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: Christian Rommel, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 42,777,061AGAINST: 162,398
Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election or re-election of the members to the Board of Directors and the Chairman: Election of Christian Rommel, Ph.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Christian Rommel, Ph.D.”): 42,777,061 for, 162,398 against, per its Form 8-K filed June 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members and Chair of the Board of Directors Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., and Douglas A. Treco, Ph.D. were each duly re-elec…”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,945,466 for, 1,000 unknown.

FOR
FOR: 17,945,466UNKNOWN: 1,000
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Election of Christian Romme” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Sandesh Mahatme, LL.M.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 42,762,070AGAINST: 177,633
Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election or re-election of the members to the Board of Directors and the Chairman: Election of Sandesh Mahatme, LL.M.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Sandesh Mahatme, LL.M.”): 42,762,070 for, 177,633 against, per its Form 8-K filed June 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members and Chair of the Board of Directors Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., and Douglas A. Treco, Ph.D. were each duly re-elec…”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,945,466 for, 1,000 unknown.

FOR
FOR: 17,945,466UNKNOWN: 1,000
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Election of Sandesh Mahatme” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Douglas A. Treco, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 40,807,871AGAINST: 2,133,551

Prior year: 91.4% for (June 8, 2023 meeting) ▲ 3.6 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Douglas A. Treco, Ph.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Douglas A. Treco, Ph.D.”): 40,807,871 for, 2,133,551 against, per its Form 8-K filed June 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members and Chair of the Board of Directors Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., and Douglas A. Treco, Ph.D. were each duly re-elec…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,672,491 for, 272,975 against, 1,000 unknown.

FOR
FOR: 17,672,491AGAINST: 272,975UNKNOWN: 1,000
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Douglas A. T” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock0234,394 00Against
Fidelity104,51938,112 00Mixed
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Katherine A. High, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 42,672,595AGAINST: 274,928

Prior year: 99.1% for (June 8, 2023 meeting) ▲ 0.3 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Katherine A. High, M.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Katherine A. High, M.D.”): 42,672,595 for, 274,928 against, per its Form 8-K filed June 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members and Chair of the Board of Directors Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., and Douglas A. Treco, Ph.D. were each duly re-elec…”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,944,998 for, 468 against, 1,000 unknown.

FOR
FOR: 17,944,998AGAINST: 468UNKNOWN: 1,000
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Katherine A.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Maria Fardis, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 42,253,383AGAINST: 689,281

Prior year: 99.3% for (June 8, 2023 meeting) ▼ 0.9 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Maria Fardis, Ph.D.

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Maria Fardis, Ph.D.”): 42,253,383 for, 689,281 against, per its Form 8-K filed June 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members and Chair of the Board of Directors Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., and Douglas A. Treco, Ph.D. were each duly re-elec…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,945,466 for, 1,000 unknown.

FOR
FOR: 17,945,466UNKNOWN: 1,000
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Maria Fardis” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Elect Director: Samarth Kulkarni, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 42,442,977AGAINST: 503,265

Prior year: 97.6% for (June 8, 2023 meeting) ▲ 1.3 pts

Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Samarth Kulkarni, Ph.D., as member and election as Chairman

CRISPR THERAPEUTICS AG’s own tally for this item (“Elect Director: Samarth Kulkarni, Ph.D.”): 42,442,977 for, 503,265 against, per its Form 8-K filed June 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 4 – Election or Re-election of the Members and Chair of the Board of Directors Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., and Douglas A. Treco, Ph.D. were each duly re-elec…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,945,346 for, 120 against, 1,000 unknown.

FOR
FOR: 17,945,346AGAINST: 120UNKNOWN: 1,000
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Samarth Kulk” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Re-election of the independent voting rights representative.

No official matchCORPORATE GOVERNANCE

Combines 5 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: votes by 63 asset managers

The 63 asset managers below reported 17,945,466 for, 1,000 unknown. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 17,945,466UNKNOWN: 1,000
Largest asset managers voting on “Re-election of the independent voting rights representative.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Binding vote on maximum equity for members of the Board of Directors from the 2024 Annual General Meeting to the 2025…

Combines 7 wordings of this item as funds reported it.

88% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 53 asset managers

Description as filed by funds: Binding vote on maximum equity for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 44 asset managers voting on “Binding vote on maximum equity for members of the Board of Directors from the 2024 Annual General Meeting to t” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
Charles Schwab0669,580 00Against
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable0125,464 00Against
State Street0107,434 00Against
Global X075,358 00Against
Lincoln Financial071,808 00Against
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust029,503 00Against
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
Capitol Series Trust018,000 00Against
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
AMERICAN BEACON FUNDS11,8710 00For
Listed Funds Trust010,557 00Against
Goldman Sachs010,005 00Against
Federated Hermes8,8400 00For
ARK Venture Fund7,2580 00For

Fund voting reports, all 44 managers: 8,939,895 for, 1,369,679 against, 4,000 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 8 asset managers voting on “Binding vote on maximum equity for members of the Board of Directors from the 2024 Annual General Meeting to t” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
Janney Montgomery Scott LLC09,562 00Against
Jasper Ridge Partners, L.P.7,4540 00For
L. Roy Papp & Associates, LLP00 00--
HOLLENCREST CAPITAL MANAGEMENT6000 00For
Keel Point, LLC0370 00Against
HOWLAND CAPITAL MANAGEMENT LLC1100 00For

Institutional-manager reports, all 8 managers: 1,557,143 for, 9,932 against, 1,000 unknown.

Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Ali Behbahani, M.D.

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

65% of fund votes cast · no official result

FORAGAINST
Details: votes by 36 asset managers

The 36 asset managers below reported 6,194,677 for, 3,313,394 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 6,194,677AGAINST: 3,313,394
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Ali Behbahan” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price01,488,390 00Against
Vanguard0874,759 00Against
BlackRock0234,394 00Against
Fidelity0142,631 00Against
Equitable0125,464 00Against
State Street0107,434 00Against
Lincoln Financial071,808 00Against
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust029,503 00Against
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
American Century015,793 00Against
Northwestern Mutual014,200 00Against
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
Listed Funds Trust010,557 00Against
Goldman Sachs010,005 00Against
MassMutual01,338 00Against
ETFis Series Trust I01,321 00Against
Franklin Templeton01,305 00Against
First Trust01,231 00Against
AQR01,146 00Against
Empower0597 00Against

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Election or re-election of the members to the Board of Directors and the…: Re-election of H. Edward Fleming, Jr., M.D.

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

97% of fund votes cast · no official result

FOR
Details: description as filed, votes by 36 asset managers

Description as filed by funds: Election or re-election of the members to the Board of Directors and the Chairman: Re-election of H. Edward Fleming, Jr., M.D.

The 36 asset managers below reported 9,191,116 for, 316,955 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,191,116AGAINST: 316,955
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of H. Edward Fl” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
BlackRock234,3940 00For
Fidelity38,112104,519 00Mixed
Equitable125,4640 00For
State Street107,4340 00For
Lincoln Financial71,8080 00For
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
Listed Funds Trust010,557 00Against
Goldman Sachs10,0050 00For
MassMutual1,3380 00For
ETFis Series Trust I01,321 00Against
Franklin Templeton01,305 00Against
First Trust01,231 00Against
AQR01,146 00Against
Empower5970 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Election or re-election of the members to the Board of Directors and the Chairman: Re-election of John T. Greene

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

97% of fund votes cast · no official result

FOR
Details: votes by 36 asset managers

The 36 asset managers below reported 9,191,489 for, 316,582 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,191,489AGAINST: 316,582
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of John T. Gree” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
BlackRock234,3940 00For
Fidelity38,112104,519 00Mixed
Equitable125,4640 00For
State Street107,4340 00For
Lincoln Financial71,8080 00For
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
Listed Funds Trust010,557 00Against
Goldman Sachs10,0050 00For
MassMutual1,3380 00For
ETFis Series Trust I01,321 00Against
Franklin Templeton01,305 00Against
First Trust01,231 00Against
AQR01,146 00Against
Empower5970 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Simeon J. George, M.D.

No official matchDIRECTOR ELECTIONS

Combines 2 wordings of this item as funds reported it.

94% of fund votes cast · no official result

FOR
Details: votes by 36 asset managers

The 36 asset managers below reported 8,918,983 for, 589,088 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 8,918,983AGAINST: 589,088
Largest asset managers voting on “Election or re-election of the members to the Board of Directors and the Chairman: Re-election of Simeon J. Ge” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
BlackRock0234,394 00Against
Fidelity0142,631 00Against
Equitable125,4640 00For
State Street107,4340 00For
Lincoln Financial71,8080 00For
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
Listed Funds Trust010,557 00Against
Goldman Sachs10,0050 00For
MassMutual1,3380 00For
ETFis Series Trust I01,321 00Against
Franklin Templeton01,305 00Against
First Trust01,231 00Against
AQR01,146 00Against
Empower5970 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Re-election of the members of the Compensation Committee: Re-election of Ali Behbahani, M.D.

No official matchDIRECTOR ELECTIONSCORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

65% of fund votes cast · no official result

FORAGAINST
Details: votes by 36 asset managers

The 36 asset managers below reported 6,194,677 for, 3,313,394 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 6,194,677AGAINST: 3,313,394
Largest asset managers voting on “Re-election of the members of the Compensation Committee: Re-election of Ali Behbahani, M.D.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price01,488,390 00Against
Vanguard0874,759 00Against
BlackRock0234,394 00Against
Fidelity0142,631 00Against
Equitable0125,464 00Against
State Street0107,434 00Against
Lincoln Financial071,808 00Against
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust029,503 00Against
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
American Century015,793 00Against
Northwestern Mutual014,200 00Against
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
Listed Funds Trust010,557 00Against
Goldman Sachs010,005 00Against
MassMutual01,338 00Against
ETFis Series Trust I01,321 00Against
Franklin Templeton01,305 00Against
First Trust01,231 00Against
AQR01,146 00Against
Empower0597 00Against

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Re-election of the members of the Compensation Committee: Re-election of H. Edward Fleming, Jr., M.D.

No official matchDIRECTOR ELECTIONSCORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

96% of fund votes cast · no official result

FOR
Details: votes by 36 asset managers

The 36 asset managers below reported 9,146,953 for, 361,118 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,146,953AGAINST: 361,118
Largest asset managers voting on “Re-election of the members of the Compensation Committee: Re-election of H. Edward Fleming, Jr., M.D.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
BlackRock234,3940 00For
Fidelity38,112104,519 00Mixed
Equitable124,2941,170 00For
State Street107,4340 00For
Lincoln Financial71,8080 00For
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
Listed Funds Trust010,557 00Against
Goldman Sachs10,0050 00For
MassMutual1,3380 00For
ETFis Series Trust I01,321 00Against
Franklin Templeton01,305 00Against
First Trust01,231 00Against
AQR01,146 00Against
Empower5970 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Re-election of the members of the Compensation Committee: Re-election of John T. Greene

No official matchDIRECTOR ELECTIONSCORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

96% of fund votes cast · no official result

FOR
Details: votes by 36 asset managers

The 36 asset managers below reported 9,147,326 for, 360,745 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,147,326AGAINST: 360,745
Largest asset managers voting on “Re-election of the members of the Compensation Committee: Re-election of John T. Greene” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
BlackRock234,3940 00For
Fidelity38,112104,519 00Mixed
Equitable124,2941,170 00For
State Street107,4340 00For
Lincoln Financial71,8080 00For
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
Listed Funds Trust010,557 00Against
Goldman Sachs10,0050 00For
MassMutual1,3380 00For
ETFis Series Trust I01,321 00Against
Franklin Templeton01,305 00Against
First Trust01,231 00Against
AQR01,146 00Against
Empower5970 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Re-election of the members of the Compensation Committee: Re-election of Simeon J. George, M.D.

No official matchDIRECTOR ELECTIONSCORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

93% of fund votes cast · no official result

FOR
Details: votes by 36 asset managers

The 36 asset managers below reported 8,874,820 for, 633,251 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 8,874,820AGAINST: 633,251
Largest asset managers voting on “Re-election of the members of the Compensation Committee: Re-election of Simeon J. George, M.D.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
BlackRock0234,394 00Against
Fidelity0142,631 00Against
Equitable124,2941,170 00For
State Street107,4340 00For
Lincoln Financial71,8080 00For
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
Listed Funds Trust010,557 00Against
Goldman Sachs10,0050 00For
MassMutual1,3380 00For
ETFis Series Trust I01,321 00Against
Franklin Templeton01,305 00Against
First Trust01,231 00Against
AQR01,146 00Against
Empower5970 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2024…

Combines 6 wordings of this item as funds reported it.

99.8% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 21 asset managers

Description as filed by funds: Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 10 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Charles Schwab669,5800 00For
Global X75,3580 00For
Capitol Series Trust18,0000 00For
AMERICAN BEACON FUNDS11,8710 00For
Federated Hermes8,8400 00For
ARK Venture Fund7,2580 00For
VanEck ETF Trust6,9980 00For
WILLIAMSBURG INVESTMENT TRUST04,000 00Against
Collaborative Investment Series Trust3,5000 00For
Putnam4680 00For

Fund voting reports, all 10 managers: 801,873 for, 4,000 against.

Institutional-manager reports: 10 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Board of Directors from the 2” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
Janney Montgomery Scott LLC9,5620 00For
Jasper Ridge Partners, L.P.7,4540 00For
L. Roy Papp & Associates, LLP00 00--
HOLLENCREST CAPITAL MANAGEMENT6000 00For
EXENCIAL WEALTH ADVISORS, LLC3180 00For
HOWLAND CAPITAL MANAGEMENT LLC1100 00For
Cannon Financial Strategists, Inc.570 00For
Belpointe Asset Management LLC410 00For

Institutional-manager reports, all 10 managers: 1,567,121 for, 1,000 unknown.

Re-election of the members of the Compensation Committee: Ali Behbahani

No official matchCORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

89% of fund votes cast · no official result

FOR
Details: votes by 21 asset managers

The 21 asset managers below reported 7,489,911 for, 920,745 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,489,911AGAINST: 920,745
Largest asset managers voting on “Re-election of the members of the Compensation Committee: Ali Behbahani” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Charles Schwab0669,580 00Against
Natixis089,596 00Against
Global X075,358 00Against
Jackson National34,16234,270 00Mixed
Capitol Series Trust018,000 00Against
ADVISORS SERIES TRUST17,3100 00For
Loomis Sayles09,378 00Against
Federated Hermes8,8400 00For
VanEck ETF Trust06,998 00Against
Allianz06,152 00Against
John Hancock03,929 00Against
AMG Funds I03,641 00Against
EA Series Trust1,9940 00For
JPMorgan01,297 00Against
Jacob Funds Inc.1,2030 00For
TRUST FOR PROFESSIONAL MANAGERS0914 00Against
CITY NATIONAL ROCHDALE FUNDS0664 00Against
Pacer Funds Trust0500 00Against
Putnam0468 00Against
Amplify ETF Trust1200 00For

Re-election of the members of the Compensation Committee: H. Edward Fleming, Jr.

No official matchCORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

92% of fund votes cast · no official result

FOR
Details: votes by 21 asset managers

The 21 asset managers below reported 7,730,172 for, 680,484 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,730,172AGAINST: 680,484
Largest asset managers voting on “Re-election of the members of the Compensation Committee: H. Edward Fleming, Jr.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Charles Schwab0669,580 00Against
Natixis89,5960 00For
Global X75,3580 00For
Jackson National68,4320 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
Loomis Sayles9,3780 00For
Federated Hermes8,8400 00For
VanEck ETF Trust6,9980 00For
Allianz06,152 00Against
John Hancock913,838 00Against
AMG Funds I3,6410 00For
EA Series Trust1,9940 00For
JPMorgan1,2970 00For
Jacob Funds Inc.1,2030 00For
TRUST FOR PROFESSIONAL MANAGERS0914 00Against
CITY NATIONAL ROCHDALE FUNDS6640 00For
Pacer Funds Trust5000 00For
Putnam4680 00For
Amplify ETF Trust1200 00For

Re-election of the members of the Compensation Committee: John T. Greene

No official matchCORPORATE GOVERNANCE

92% of fund votes cast · no official result

FOR
Details: votes by 21 asset managers

The 21 asset managers below reported 7,730,172 for, 680,484 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,730,172AGAINST: 680,484
Largest asset managers voting on “Re-election of the members of the Compensation Committee: John T. Greene” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Charles Schwab0669,580 00Against
Natixis89,5960 00For
Global X75,3580 00For
Jackson National68,4320 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
Loomis Sayles9,3780 00For
Federated Hermes8,8400 00For
VanEck ETF Trust6,9980 00For
Allianz06,152 00Against
John Hancock913,838 00Against
AMG Funds I3,6410 00For
EA Series Trust1,9940 00For
JPMorgan1,2970 00For
Jacob Funds Inc.1,2030 00For
TRUST FOR PROFESSIONAL MANAGERS0914 00Against
CITY NATIONAL ROCHDALE FUNDS6640 00For
Pacer Funds Trust5000 00For
Putnam4680 00For
Amplify ETF Trust1200 00For

Re-election of the members of the Compensation Committee: Simeon J. George

No official matchCORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

91% of fund votes cast · no official result

FOR
Details: votes by 21 asset managers

The 21 asset managers below reported 7,623,714 for, 786,942 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,623,714AGAINST: 786,942
Largest asset managers voting on “Re-election of the members of the Compensation Committee: Simeon J. George” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Charles Schwab0669,580 00Against
Natixis89,5960 00For
Global X075,358 00Against
Jackson National68,4320 00For
Capitol Series Trust018,000 00Against
ADVISORS SERIES TRUST17,3100 00For
Loomis Sayles9,3780 00For
Federated Hermes8,8400 00For
VanEck ETF Trust06,998 00Against
Allianz06,152 00Against
John Hancock913,838 00Against
AMG Funds I03,641 00Against
EA Series Trust1,9940 00For
JPMorgan01,297 00Against
Jacob Funds Inc.1,2030 00For
TRUST FOR PROFESSIONAL MANAGERS0914 00Against
CITY NATIONAL ROCHDALE FUNDS0664 00Against
Pacer Funds Trust0500 00Against
Putnam4680 00For
Amplify ETF Trust1200 00For

Approval of Amendments to the Articles of Association to Facilitate the Use of Equity Compensation and Pension Benefits…

Official resultCOMPENSATIONCORPORATE GOVERNANCEReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

79% Approved · of votes cast

FOR 79%AGAINST
FOR: 33,909,689AGAINST: 8,995,908
Details: description as filed, official tally, votes by 70 asset managers

Description as filed by funds: Approval of amendments to the Articles of Association to facilitate the use of equity compensation and pension benefits programs consistent with current market practices.

CRISPR THERAPEUTICS AG’s own tally for this item (“10. Approval of Amendments to the Articles of Association to Facilitate the Use of Equity Compensation and Pension Benefits Programs Consistent with Current Market Practices”): 33,909,689 for, 8,995,908 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 10 – Approval of Amendments to the Articles of Association to Facilitate the Use of Equity Compensation and Pension Benefits Programs Consistent with Current Market Practices Amendment and restatement of 18, 32, 33, 40 and 41 of the Articles of Association to align the Company’s use of equ…”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 17,341,031 for, 605,807 against, 1,000 unknown.

FOR
FOR: 17,341,031AGAINST: 605,807UNKNOWN: 1,000
Largest asset managers voting on “Approval of amendments to the Articles of Association to facilitate the use of equity compensation and pension” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock0234,394 00Against
Fidelity104,51938,112 00Mixed
Equitable124,2941,170 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National43,48424,948 00Mixed
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust029,503 00Against
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 70 asset managers. All 70 are in the interactive database (link above).

Approval of an Increase and Certain Adjustments to the Company’s Capital Band

Official resultCAPITAL STRUCTUREReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 58,625,938AGAINST: 2,209,165
Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Approval of an increase and certain adjustments to the Company's capital band.

CRISPR THERAPEUTICS AG’s own tally for this item (“11. Approval of an Increase and Certain Adjustments to the Company’s Capital Band”): 58,625,938 for, 2,209,165 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “1 of the Articles of Association to make certain ministerial changes to such paragraph, were approved with at least two thirds of the votes represented and the absolute majority of the par value of the represented shares.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,944,998 for, 468 against, 1,000 unknown.

FOR
FOR: 17,944,998AGAINST: 468UNKNOWN: 1,000
Largest asset managers voting on “Approval of an increase and certain adjustments to the Company's capital band.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements…

Official resultOTHERReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 60,823,544AGAINST: 226,925
Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2023.

CRISPR THERAPEUTICS AG’s own tally for this item (“1. Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2023”): 60,823,544 for, 226,925 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 1 – Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2023 The Swiss management report, the consolidated financial statements and the statutory financial statements of the Com…”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,945,466 for, 1,000 unknown.

FOR
FOR: 17,945,466UNKNOWN: 1,000
Largest asset managers voting on “Approval of the Swiss management report, the consolidated financial statements and the statutory financial sta” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Approval of the Appropriation of Financial Results

Official resultCAPITAL STRUCTUREOTHERReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.5% Approved · of votes cast

FOR 99.5%
FOR: 60,715,908AGAINST: 283,326
Details: description as filed, official tally, votes by 63 asset managers

Description as filed by funds: Approval of the appropriation of financial results.

CRISPR THERAPEUTICS AG’s own tally for this item (“2. Approval of the Appropriation of Financial Results”): 60,715,908 for, 283,326 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Approval of the Appropriation of Financial Results The proposal to carry forward the net income resulting from the appropriation of financial results was approved.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 63 asset managers below reported 17,945,466 for, 1,000 unknown.

FOR
FOR: 17,945,466UNKNOWN: 1,000
Largest asset managers voting on “Approval of the appropriation of financial results.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Transact any other business that may properly come before the 2024 Annual General Meeting or any adjournment or…

Combines 5 wordings of this item as funds reported it.

42% of fund votes cast · no official result

FORAGAINST
Details: description as filed, votes by 63 asset managers

Description as filed by funds: Transact any other business that may properly come before the 2024 Annual General Meeting or any adjournment or postponement thereof.

The 63 asset managers below reported 7,506,993 for, 10,436,479 against, 1,994 abstained, 1,000 unknown. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,506,993AGAINST: 10,436,479ABSTAIN: 1,994UNKNOWN: 1,000
Largest asset managers voting on “Transact any other business that may properly come before the 2024 Annual General Meeting or any adjournment o” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group06,194,677 00Against
T. Rowe Price01,488,390 00Against
Vanguard0874,759 00Against
Charles Schwab0669,580 00Against
BlackRock0234,394 00Against
Fidelity0142,631 00Against
Equitable0125,464 00Against
State Street0107,434 00Against
Natixis089,596 00Against
Global X075,358 00Against
Lincoln Financial071,808 00Against
Jackson National34,16234,270 00Mixed
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust029,503 00Against
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
Capitol Series Trust018,000 00Against
ADVISORS SERIES TRUST17,3100 00For
American Century015,793 00Against
Northwestern Mutual014,200 00Against
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).

Approval of Amendment to the 2018 Stock Option and Incentive Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

80% Approved · of votes cast

FOR 80%AGAINST
FOR: 34,337,953AGAINST: 8,532,315
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Approval of an amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.

CRISPR THERAPEUTICS AG’s own tally for this item (“9. Approval of Amendment to the 2018 Stock Option and Incentive Plan”): 34,337,953 for, 8,532,315 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 9 – Approval of Amendment to the 2018 Stock Option and Incentive Plan The Plan Amendment was approved.”
Support: 80% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 17,501,612 for, 440,652 against, 10,500 abstained, 1,000 unknown.

FOR
FOR: 17,501,612AGAINST: 440,652ABSTAIN: 10,500UNKNOWN: 1,000
Largest asset managers voting on “Approval of an amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable124,2941,170 00For
State Street0107,434 00Against
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National43,48424,948 00Mixed
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust029,503 00Against
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
Capitol Series Trust18,0000 00For
ADVISORS SERIES TRUST17,3100 00For
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Approval of an Increase in the Conditional Share Capital for Employee Equity Plans

Official resultCAPITAL STRUCTUREReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

76% Approved · of votes cast

FOR 76%AGAINST
FOR: 32,512,494AGAINST: 10,394,452

Prior year: 67.8% for (June 8, 2023 meeting) ▲ 8.0 pts

Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Approval of an increase of the conditional share capital for employee equity plans.

CRISPR THERAPEUTICS AG’s own tally for this item (“8. Approval of an Increase in the Conditional Share Capital for Employee Equity Plans”): 32,512,494 for, 10,394,452 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 8 – Approval of an Increase in the Conditional Share Capital for Employee Equity Plans An increase in the Company’s conditional share capital for employee equity plans was approved with at least two thirds of the votes represented and the absolute majority of the par value of the represent…”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 16,731,463 for, 1,214,603 against, 1,000 unknown.

FOR
FOR: 16,731,463AGAINST: 1,214,603UNKNOWN: 1,000
Largest asset managers voting on “Approval of an increase of the conditional share capital for employee equity plans.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
Charles Schwab0669,580 00Against
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable124,2941,170 00For
State Street0107,434 00Against
Natixis89,5960 00For
Global X075,358 00Against
Lincoln Financial71,8080 00For
Jackson National43,48424,948 00Mixed
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust029,503 00Against
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
Capitol Series Trust018,000 00Against
ADVISORS SERIES TRUST17,3100 00For
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending…

Combines 8 wordings of this item as funds reported it.

96% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 60 asset managers

Description as filed by funds: Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2024.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 44 asset managers voting on “Binding vote on maximum variable compensation for members of the Executive Committee for the current year endi” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity38,112104,519 00Mixed
Equitable124,2941,170 00For
State Street0107,434 00Against
Global X75,3580 00For
Lincoln Financial71,8080 00For
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust029,503 00Against
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
Capitol Series Trust18,0000 00For
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
AMERICAN BEACON FUNDS11,8710 00For
Listed Funds Trust010,557 00Against
Goldman Sachs010,005 00Against
Federated Hermes8,8400 00For
ARK Venture Fund7,2580 00For

Fund voting reports, all 44 managers: 9,801,884 for, 511,690 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 14 asset managers voting on “Binding vote on maximum variable compensation for members of the Executive Committee for the current year endi” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
EcoR1 Capital, LLC1,389,2760 00For
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
Janney Montgomery Scott LLC9,5620 00For
Jasper Ridge Partners, L.P.7,4540 00For
L. Roy Papp & Associates, LLP00 00--
HOLLENCREST CAPITAL MANAGEMENT6000 00For
Keel Point, LLC0370 00Against
EXENCIAL WEALTH ADVISORS, LLC3180 00For
MERIDIAN MANAGEMENT CO2000 00For
HOWLAND CAPITAL MANAGEMENT LLC1100 00For
HOHIMER WEALTH MANAGEMENT, LLC1020 00For
HoyleCohen, LLC650 00For
Belpointe Asset Management LLC410 00For

Institutional-manager reports, all 14 managers: 2,956,707 for, 370 against, 1,000 unknown.

Binding vote on maximum equity for members of the Executive Committee from the 2024 Annual General Meeting to the 2025…

Combines 7 wordings of this item as funds reported it.

87% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 55 asset managers

Description as filed by funds: Binding vote on maximum equity for members of the Executive Committee from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 44 asset managers voting on “Binding vote on maximum equity for members of the Executive Committee from the 2024 Annual General Meeting to ” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
Charles Schwab0669,580 00Against
BlackRock0234,394 00Against
Fidelity0142,631 00Against
Equitable124,2941,170 00For
State Street0107,434 00Against
Global X075,358 00Against
Lincoln Financial71,8080 00For
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust029,503 00Against
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
Capitol Series Trust018,000 00Against
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
AMERICAN BEACON FUNDS11,8710 00For
Listed Funds Trust010,557 00Against
Goldman Sachs010,005 00Against
Federated Hermes8,8400 00For
ARK Venture Fund7,2580 00For

Fund voting reports, all 44 managers: 8,758,974 for, 1,550,600 against, 4,000 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 10 asset managers voting on “Binding vote on maximum equity for members of the Executive Committee from the 2024 Annual General Meeting to ” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
Janney Montgomery Scott LLC09,562 00Against
Jasper Ridge Partners, L.P.7,4540 00For
L. Roy Papp & Associates, LLP00 00--
HOLLENCREST CAPITAL MANAGEMENT6000 00For
Keel Point, LLC0370 00Against
HOWLAND CAPITAL MANAGEMENT LLC1100 00For
HOHIMER WEALTH MANAGEMENT, LLC1020 00For
HoyleCohen, LLC650 00For

Institutional-manager reports, all 10 managers: 1,557,310 for, 9,932 against, 1,000 unknown.

Non-Binding Advisory Vote on the Compensation Paid to Named Executive Officers Under U.S. Securities Law Requirements

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 25 wordings of this item as funds reported it.

75% Approved · of votes cast

FOR 75%AGAINST
FOR: 32,094,737AGAINST: 10,778,822

Prior year: 63.6% for (June 8, 2023 meeting) ▲ 11.2 pts

Details: description as filed, official tally, votes by 428 asset managers

Description as filed by funds: Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements

CRISPR THERAPEUTICS AG’s own tally for this item (“7. Non-Binding Advisory Vote on the Compensation Paid to Named Executive Officers Under U.S. Securities Law Requirements”): 32,094,737 for, 10,778,822 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 7 – Non-Binding Advisory Vote on the Compensation Paid to Named Executive Officers Under U.S. Securities Law Requirements The compensation paid to the named executive officers was approved on a non-binding basis.”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 60 asset managers voting on “Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securi” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
Charles Schwab0669,580 00Against
BlackRock0234,394 00Against
Fidelity0142,631 00Against
Equitable124,2941,170 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X075,358 00Against
Lincoln Financial71,8080 00For
Jackson National43,48424,948 00Mixed
Allspring059,074 00Against
Investment Managers Series Trust II41,6130 00For
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
Capitol Series Trust018,000 00Against
ADVISORS SERIES TRUST17,3100 00For
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against

Fund voting reports, all 60 managers: 16,538,284 for, 1,448,315 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 377 asset managers voting on “Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securi” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group7,254,8920 00For
Nikko Asset Management Americas, Inc.02,970,301 00Against
T. Rowe Price2,166,44790,151 00For
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Charles Schwab0669,580 00Against
UBS0659,393 00Against
Contrarius Investment Management Ltd655,9130 00For
Versant Venture Management, LLC500,0280 00For
Avoro Capital Advisors LLC419,5800 00For
Man Group plc0323,770 00Against
JPMorgan298,6024,337 00For
Nikko Asset Management Co., Ltd.0286,772 00Against
BlackRock5,608262,900 00Against
Fidelity0233,910 00Against
CAPITAL ADVISORS INC/OK231,5920 00For
BAILLIE GIFFORD & CO LTD0223,818 00Against
Vestmark Advisory Solutions, Inc.0202,549 00Against
State Street173,3752,441 00For
Northern Trust125,33711,555 00Mixed
Lazard0110,978 00Against
BLAIR WILLIAM & CO/IL099,996 00Against
ARMISTICE CAPITAL, LLC82,8110 00For
Reynders McVeigh Capital Management, LLC082,478 00Against
Integral Health Asset Management, LLC81,4830 00For
ROCKEFELLER FINANCIAL LLC76,7530 00For

Institutional-manager reports, all 377 managers: 13,532,666 for, 7,370,232 against, 2,944 withheld, 413 abstained, 102 not voted, 1,000 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Non-binding advisory vote on the 2023 Compensation Report.

Combines 7 wordings of this item as funds reported it.

88% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 77 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 44 asset managers voting on “Non-binding advisory vote on the 2023 Compensation Report.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
Charles Schwab0669,580 00Against
BlackRock0234,394 00Against
Fidelity0142,631 00Against
Equitable124,2941,170 00For
State Street107,4340 00For
Global X075,358 00Against
Lincoln Financial71,8080 00For
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
Capitol Series Trust018,000 00Against
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
AMERICAN BEACON FUNDS11,8710 00For
Listed Funds Trust010,557 00Against
Goldman Sachs10,0050 00For
Federated Hermes8,8400 00For
ARK Venture Fund7,2580 00For

Fund voting reports, all 44 managers: 8,909,916 for, 1,403,658 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 29 asset managers voting on “Non-binding advisory vote on the 2023 Compensation Report.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
Sand Hill Global Advisors, LLC08,735 00Against
Jasper Ridge Partners, L.P.7,4540 00For
CWM, LLC5,0900 00For
LINCOLN CAPITAL CORP3,0000 00For
Atlantic Union Bankshares Corp01,200 00Against
PETREDIS INVESTMENT ADVISORS LLC1,1600 00For
L. Roy Papp & Associates, LLP00 00--
TRUST CO OF OKLAHOMA7500 00For
HOLLENCREST CAPITAL MANAGEMENT6000 00For
EVERGREEN CAPITAL MANAGEMENT LLC5990 00For
Bath Savings Trust Co5500 00For
FINANCIAL COUNSELORS INC0417 00Against
Keel Point, LLC0370 00Against
EXENCIAL WEALTH ADVISORS, LLC3180 00For
Sonora Investment Management Group, LLC3150 00For
MERIDIAN MANAGEMENT CO2000 00For
HOWLAND CAPITAL MANAGEMENT LLC1100 00For
Somerset Trust Co0106 00Against
FIRST UNITED BANK & TRUST0100 00Against
NAPLES GLOBAL ADVISORS, LLC1000 00For
Orion Porfolio Solutions, LLC088 00Against
Orion Portfolio Solutions, LLC088 00Against
Savant Capital, LLC071 00Against

Institutional-manager reports, all 29 managers: 1,569,356 for, 11,216 against, 1,000 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Approval of the compensation for the Board of Directors and…: Non-binding advisory vote on the 2023 Compensation Report

Combines 2 wordings of this item as funds reported it.

99.4% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 69 asset managers

Description as filed by funds: Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2023 Compensation Report: Non-binding advisory vote on the 2023 Compensation Report

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 15 asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Natixis89,5960 00For
Jackson National43,48424,948 00Mixed
ADVISORS SERIES TRUST17,3100 00For
Loomis Sayles9,3780 00For
Allianz06,152 00Against
John Hancock913,838 00Against
AMG Funds I03,641 00Against
EA Series Trust1,9940 00For
JPMorgan1,2970 00For
Jacob Funds Inc.1,2030 00For
TRUST FOR PROFESSIONAL MANAGERS0914 00Against
CITY NATIONAL ROCHDALE FUNDS0664 00Against
Pacer Funds Trust0500 00Against
Amplify ETF Trust1200 00For

Fund voting reports, all 15 managers: 7,590,755 for, 40,657 against.

Institutional-manager reports: 55 asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
CAPITAL ADVISORS INC/OK231,5920 00For
ROCKEFELLER FINANCIAL LLC76,7530 00For
Carnegie Investment Counsel67,3400 00For
BOSTON FAMILY OFFICE LLC00 9,3500Abstain
DEARBORN PARTNERS LLC3,5500 00For
RAYMOND JAMES & ASSOCIATES02,689 00Against
MERCER GLOBAL ADVISORS INC /ADV1,7350 00For
WESTWOOD HOLDINGS GROUP INC01,461 00Against
Clear Harbor Asset Management, LLC1,3430 00For
RWA WEALTH PARTNERS, LLC1,1500 00For
COBBLESTONE CAPITAL ADVISORS LLC /NY/1,0270 00For
SPIREPOINT PRIVATE CLIENT, LLC1,0000 00For
SCHAPER BENZ & WISE INVESTMENT COUNSEL INC/WI8600 00For
Aljian Capital Management, LLC7450 00For
OAK HILL WEALTH ADVISORS, LLC6350 00For
BOKF, NA6250 00For
BARLOW WEALTH PARTNERS, INC.6000 00For
FineMark National Bank & Trust5350 00For
DAVENPORT & Co LLC0529 00Against
FERGUSON WELLMAN CAPITAL MANAGEMENT, INC0528 00Against
AMG National Trust Bank5050 00For
COUNTRY TRUST BANK5000 00For
M. Kulyk & Associates, LLC4360 00For
FIRST MANHATTAN CO. LLC.4150 00For
APPLETON PARTNERS INC/MA0400 00Against

Institutional-manager reports, all 55 managers: 393,275 for, 6,725 against, 9,350 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July 1, 2024…

Combines 8 wordings of this item as funds reported it.

96% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 59 asset managers

Description as filed by funds: Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July 1, 2024 to June 30, 2025.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 44 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
Capital Group6,194,6770 00For
T. Rowe Price1,445,74842,642 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity38,112104,519 00Mixed
Equitable124,2941,170 00For
State Street0107,434 00Against
Global X75,3580 00For
Lincoln Financial71,8080 00For
Allspring059,074 00Against
Direxion Shares ETF Trust030,040 00Against
Nushares ETF Trust029,503 00Against
RMB INVESTORS TRUST029,295 00Against
Guggenheim026,467 00Against
ProShares022,917 00Against
Capitol Series Trust18,0000 00For
American Century015,793 00Against
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST011,979 00Against
AMERICAN BEACON FUNDS11,8710 00For
Listed Funds Trust010,557 00Against
Goldman Sachs010,005 00Against
Federated Hermes8,8400 00For
ARK Venture Fund7,2580 00For

Fund voting reports, all 44 managers: 9,801,884 for, 511,690 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 13 asset managers voting on “Binding vote on maximum non- performance-related compensation for members of the Executive Committee from July” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
SR ONE CAPITAL MANAGEMENT, LP1,048,9510 00For
Versant Venture Management, LLC500,0280 00For
Janney Montgomery Scott LLC9,5620 00For
Jasper Ridge Partners, L.P.7,4540 00For
L. Roy Papp & Associates, LLP00 00--
HOLLENCREST CAPITAL MANAGEMENT6000 00For
Keel Point, LLC0370 00Against
EXENCIAL WEALTH ADVISORS, LLC3180 00For
River Wealth Advisors LLC1350 00For
HOWLAND CAPITAL MANAGEMENT LLC1100 00For
HOHIMER WEALTH MANAGEMENT, LLC1020 00For
HoyleCohen, LLC650 00For
Belpointe Asset Management LLC410 00For

Institutional-manager reports, all 13 managers: 1,567,366 for, 370 against, 1,000 unknown.

Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on…

No official matchCOMPENSATION

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 49 asset managers

Description as filed by funds: Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2023 Compensation Report: Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2024 Annual General Meeting to the 2025 annual general meeting of shareholders.

The 49 asset managers below reported 17,128,556 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 17,128,556
Largest asset managers voting on “Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory v” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
Goldman Sachs10,0050 00For
Loomis Sayles9,3780 00For
Allianz6,1520 00For
John Hancock3,9290 00For

Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).

Re-election of the Auditors

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 60,337,355AGAINST: 352,399
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: Re-election of the auditors.

CRISPR THERAPEUTICS AG’s own tally for this item (“13. Re-election of the Auditors”): 60,337,355 for, 352,399 against, per its Form 8-K filed June 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 17,926,884 for, 582 against, 18,020 abstained, 1,000 unknown.

FOR
FOR: 17,926,884AGAINST: 582ABSTAIN: 18,020UNKNOWN: 1,000
Largest asset managers voting on “Re-election of the auditors.” at CRISPR THERAPEUTICS AG, 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust7,426,2820 00For
Capital Group6,194,6770 00For
T. Rowe Price1,488,3900 00For
Vanguard874,7590 00For
Charles Schwab669,5800 00For
BlackRock234,3940 00For
Fidelity142,6310 00For
Equitable125,4640 00For
State Street107,4340 00For
Natixis89,5960 00For
Global X75,3580 00For
Lincoln Financial71,8080 00For
Jackson National68,4320 00For
Allspring59,0740 00For
Direxion Shares ETF Trust30,0400 00For
Nushares ETF Trust29,5030 00For
RMB INVESTORS TRUST29,2950 00For
Guggenheim26,4670 00For
ProShares22,9170 00For
Capitol Series Trust00 18,0000Abstain
ADVISORS SERIES TRUST17,3100 00For
American Century15,7930 00For
Northwestern Mutual14,2000 00For
EXCHANGE TRADED CONCEPTS TRUST11,9790 00For
AMERICAN BEACON FUNDS11,8710 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of June 5, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest CRISPR THERAPEUTICS AG shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 84,837,610 shares outstanding at the time of that meeting.

Fund voting reports: top CRISPR THERAPEUTICS AG shareholders by shares voted on “Non-binding advisory vote on the compensation paid to the Company's named executive officers…”, 2023-2024
#Asset manager % of shares outstanding
1ARK ETF Trust 8.75%
2Capital Group 7.30%
3T. Rowe Price 1.75%
4Vanguard 1.03%
5Charles Schwab 0.79%
6BlackRock 0.28%
7Fidelity 0.17%
8Equitable 0.15%
9State Street 0.13%
10Natixis 0.11%
Institutional-manager reports: top CRISPR THERAPEUTICS AG shareholders by shares voted on “Non-binding advisory vote on the compensation paid to the Company's named executive officers…”, 2023-2024
#Asset manager % of shares outstanding
1Capital Group 8.55%
2Nikko Asset Management Americas, Inc. 3.50%
3T. Rowe Price 2.66%
4SR ONE CAPITAL MANAGEMENT, LP 1.24%
5Charles Schwab 0.79%
6UBS 0.78%
7Contrarius Investment Management Ltd 0.77%
8Versant Venture Management, LLC 0.59%
9Avoro Capital Advisors LLC 0.49%
10Man Group plc 0.38%

Reported CRISPR THERAPEUTICS AG holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

CRISPR THERAPEUTICS AG holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
ARK Investment Management LLC9,122,493 10.75%Schedule 13G, filed December 10, 2024
BlackRock7,050,145 8.31%Form 13F, quarter ended March 31, 2024
Capital Research and Management Company6,420,736 7.57%Proxy statement (DEF 14A), proxy filed April 9, 2024
Vanguard Group2,364,645 2.79%Form 13F, quarter ended March 31, 2024
FMR (Fidelity)1,885,663 2.22%Form 13F, quarter ended March 31, 2024
Citadel Advisors1,557,600 1.84%Form 13F, quarter ended March 31, 2024
State Street1,495,208 1.76%Form 13F, quarter ended March 31, 2024
Samarth Kulkarni, Ph.D.1,433,121 1.69%Proxy statement (DEF 14A), proxy filed April 9, 2024
Morgan Stanley1,397,859 1.65%Form 13F, quarter ended March 31, 2024
Simeon J. George, M.D.1,172,868 1.38%Proxy statement (DEF 14A), proxy filed April 9, 2024

Percentages above are of 84,837,610 shares outstanding, as reported by CRISPR THERAPEUTICS AG on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At CRISPR THERAPEUTICS AG's shareholder meeting held May 30, 2024, in the 2023-2024 proxy season, 439 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 4,919 separate fund positions. Their filings are grouped here into 37 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Non-binding advisory vote on the compensation paid to the Company's named executive officers… — CRISPR THERAPEUTICS AG's filing reports the proposal as approved, with 75% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CRISPR THERAPEUTICS AG's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CRISPR THERAPEUTICS AG’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

CRISPR THERAPEUTICS AG proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “CRISPR THERAPEUTICS (CRSP) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/crispr-therapeutics-ag/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.